F069 Navigating the Shoals of Cutaneous T-cell Lymphoma: Challenges and Controversies
DESCRIPTION
This session will discuss challenges and controversies in CTCL, and provide practical pearls for the general dermatologist. 1. Challenging cases of CTCL that took years for diagnosis, and lessons learned 2. Mimickers of CTCL, and how to utilize tools such as flow cytometry and T-cell gene rearrangement (and pitfalls) 3. Management of CTCL in certain populations, including pediatric, pregnant, and skin of color 4. Does dupilumab cause exacerbation of CTCL? 5. JAK inhibitors and CTCL- friend or foe? We will review the evidence and discuss the potential role for JAK inhibition in treatment of CTCL.
LEARNING OBJECTIVES
Discuss diagnostic challenges in cutaneous T-cell lymphoma (CTCL), including cases that were "missed," as well as conditions that can mimic CTCL. Learn how to utilize tests that can help in challenging cases, as well as potential pitfalls in the interpretation of these tests
Describe special considerations when taking care of specific populations with CTCL, such as pediatric patients, pregnant patients or patients who are planning pregnancy, and skin of color patients
Examine the current evidence behind the controversial association between dupilumab and CTCL, and review current data regarding the relationship between JAK inhibitors and CTCL, and the potential for JAK inhibition as therapy for CTCL
SCHEDULE
3:30 PM
How to utilize IHC and molecular studies to distinguish CTCL from mimickers (and potential pitfalls)
Jina Chung, MD, FAAD
3:52 PM
Challenging cases of CTCL and lessons learned
Ellen J. Kim, MD, FAAD
4:14 PM
CTCL management in special populations
Jennifer Villasenor-Park, MD, PhD, FAAD
4:36 PM
Does dupilumab cause progression of CTCL?
Cecilia Larocca, MD, FAAD
4:58 PM
JAK inhibitors and CTCL- friend or foe?
Auris Huen, PharmD, MD, FAAD
5:20 PM
Q & A
DIRECTOR
Jina Chung, MD, FAAD
SPEAKERS
Auris Huen, PharmD, MD, FAAD
Ellen J. Kim, MD, FAAD
Cecilia Larocca, MD, FAAD
Jennifer Villasenor-Park, MD, PhD, FAAD
DISCLOSURES
Jina Chung, MD, FAAD
No financial relationships exist with ineligible companies.
Auris Huen, PharmD, MD, FAAD
CRISPR Therapeutics – Investigator(Grants/Research Funding); Innate Pharma S.A. – Investigator(Grants/Research Funding); Kymera Therapeutics – Investigator(Grants/Research Funding); Kyowa Kirin – Consultant(Honoraria); Scitech Development – Investigator(Grants/Research Funding); Seattle Genetics – Investigator(Grants/Research Funding); Soligenix, Inc – Investigator(Grants/Research Funding);
Ellen J. Kim, MD, FAAD
Galderma USA – Consultant(Honoraria), Investigator(Grants/Research Funding); Innate Pharma S.A. – Investigator(Grants/Research Funding); Solgenix LLC – Investigator(Grants/Research Funding);
Cecilia Larocca, MD, FAAD
No financial relationships exist with ineligible companies.
Jennifer Villasenor-Park, MD, PhD, FAAD
No financial relationships exist with ineligible companies.